ENSYSCE BIOSCIENCES, INC. Research and Development Expense
ENSYSCE BIOSCIENCES, INC. (ENSC) reported Research and Development Expense of $2.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- ENSYSCE BIOSCIENCES, INC. research and development expense for the quarter ending 2026-06-30 was $2.47M, a 28.51% increase year-over-year.
- ENSYSCE BIOSCIENCES, INC. research and development expense for the quarter ending 2026-03-31 was $3.35M, a 77.50% increase year-over-year.
- ENSYSCE BIOSCIENCES, INC. research and development expense for the quarter ending 2025-12-31 was $3.61M, a 4.99% decline year-over-year.
- ENSYSCE BIOSCIENCES, INC. research and development expense for the quarter ending 2025-09-30 was $2.95M, a 74.78% increase year-over-year.
- ENSYSCE BIOSCIENCES, INC. research and development expense for fiscal 2025 was $10.38M, a 43.74% increase from fiscal 2024.
- ENSYSCE BIOSCIENCES, INC. research and development expense for fiscal 2024 was $7.22M, a 4.85% decline from fiscal 2023.
- ENSYSCE BIOSCIENCES, INC. research and development expense for fiscal 2023 was $7.59M, a 61.75% decline from fiscal 2022.
- ENSYSCE BIOSCIENCES, INC. research and development expense for fiscal 2022 was $19.84M, a 322.93% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.47M 10-Q · filed 2026-08-13 | $5.82M 10-Q · filed 2026-08-13 | $9.43M derived: sum of 3 quarters · filed 2026-08-13 | $12.39M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $3.35M 10-Q · filed 2026-05-15 | $6.96M derived: sum of 2 quarters · filed 2026-05-15 | $9.91M derived: sum of 3 quarters · filed 2026-05-15 | $11.84M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $3.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $6.57M derived: sum of 2 quarters · filed 2026-03-30 | $8.49M derived: sum of 3 quarters · filed 2026-08-13 | $10.38M 10-K · filed 2026-03-30 |
| 2025-09-30 | $2.95M 10-Q · filed 2025-11-14 | $4.88M derived: sum of 2 quarters · filed 2026-08-13 | $6.76M 10-Q · filed 2025-11-14 | $10.57M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.92M 10-Q · filed 2026-08-13 | $3.81M 10-Q · filed 2026-08-13 | $7.61M derived: sum of 3 quarters · filed 2026-08-13 | $9.30M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.89M 10-Q · filed 2026-05-15 | $5.69M derived: sum of 2 quarters · filed 2026-05-15 | $7.38M derived: sum of 3 quarters · filed 2026-05-15 | $8.33M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $3.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $5.49M derived: sum of 2 quarters · filed 2026-03-30 | $6.44M derived: sum of 3 quarters · filed 2026-03-30 | $7.22M 10-K · filed 2026-03-30 |
| 2024-09-30 | $1.69M 10-Q · filed 2025-11-14 | $2.64M derived: sum of 2 quarters · filed 2025-11-14 | $3.42M 10-Q · filed 2025-11-14 | $5.65M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $947.23K 10-Q · filed 2025-08-13 | $1.73M 10-Q · filed 2025-08-13 | $3.96M derived: sum of 3 quarters · filed 2025-08-13 | $5.87M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $778.90K 10-Q · filed 2025-05-13 | $3.01M derived: sum of 2 quarters · filed 2025-05-13 | $4.93M derived: sum of 3 quarters · filed 2025-05-13 | $6.57M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $2.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $4.15M derived: sum of 2 quarters · filed 2025-03-10 | $5.79M derived: sum of 3 quarters · filed 2025-03-10 | $7.59M 10-K · filed 2025-03-10 |
| 2023-09-30 | $1.91M 10-Q · filed 2024-11-12 | $3.56M derived: sum of 2 quarters · filed 2024-11-12 | $5.35M 10-Q · filed 2024-11-12 | $11.80M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.64M 10-Q · filed 2024-08-14 | $3.44M 10-Q · filed 2024-08-14 | $9.88M derived: sum of 3 quarters · filed 2024-08-14 | $14.64M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $1.80M 10-Q · filed 2024-05-13 | $8.24M derived: sum of 2 quarters · filed 2024-05-13 | $12.99M derived: sum of 3 quarters · filed 2024-05-13 | $18.31M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $6.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $11.20M derived: sum of 2 quarters · filed 2024-03-15 | $16.51M derived: sum of 3 quarters · filed 2024-03-15 | $19.84M 10-K · filed 2024-03-15 |
| 2022-09-30 | $4.76M 10-Q · filed 2023-11-09 | $10.07M derived: sum of 2 quarters · filed 2023-11-09 | $13.39M 10-Q · filed 2023-11-09 | $15.40M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $5.31M 10-Q · filed 2023-08-11 | $8.45M 10-Q · filed 2023-08-11 | $10.64M derived: sum of 3 quarters · filed 2023-08-11 | $12.35M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $3.14M 10-Q · filed 2023-05-15 | $5.33M derived: sum of 2 quarters · filed 2023-05-15 | $7.04M derived: sum of 3 quarters · filed 2023-05-15 | $7.51M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $2.19M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $3.90M derived: sum of 2 quarters · filed 2023-03-30 | $4.37M derived: sum of 3 quarters · filed 2023-03-30 | $4.69M 10-K · filed 2023-03-30 |
| 2021-09-30 | $1.71M 10-Q · filed 2022-11-14 | $2.18M derived: sum of 2 quarters · filed 2022-11-14 | $2.50M 10-Q · filed 2022-11-14 | $3.72M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $463.22K 10-Q · filed 2022-08-11 | $787.60K 10-Q · filed 2022-08-11 | $2.00M derived: sum of 3 quarters · filed 2022-08-11 | $2.89M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $284.38K 10-Q · filed 2022-05-12 | $1.54M derived: sum of 2 quarters · filed 2022-05-12 | $2.43M derived: sum of 3 quarters · filed 2022-05-12 | $3.83M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $2.15M derived: sum of 2 quarters · filed 2022-03-31 | $3.55M derived: sum of 3 quarters · filed 2022-03-31 | $4.39M 10-K · filed 2022-03-31 |
| 2020-09-30 | $892.99K 10-Q · filed 2021-11-15 | $2.30M derived: sum of 2 quarters · filed 2021-11-15 | $3.14M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $1.40M 10-Q · filed 2021-08-16 | $2.24M 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |